Alicaforsen: Phase II

In a U.S Phase II trial in 31 patients with mild-to-moderate psoriasis, topical Alicaforsen significantly improved the IGRS compared to placebo at week 4 (p=0.02) but not at week 8 (p=0.206). Alicafor...